Bellicum Pharmaceuticals, Inc. Prices Initial Public Offering Of 7,350,000 Shares Of Common Stock

HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the pricing of its initial public offering of 7,350,000 shares of its common stock, an increase of 1,100,000 shares from the number of shares originally offered, at a public offering price of $19.00 per share. All of the shares of common stock are being offered by Bellicum. The Company's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading today (December 18, 2014) under the ticker symbol "BLCM." In addition, Bellicum has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the offering price.

Help employers find you! Check out all the jobs and post your resume.